カテゴリー： MarketsandMarkets, 世界, 医療/バイオ

世界の再生医療市場：製品別（細胞治療（自己、同種）、遺伝子治療、組織工学（足場、ハイドロゲル））、用途別、地域別

◆英語タイトル：Regenerative Medicine Market by Product (Cell Therapy (Autologous, Allogenic), Gene Therapy, Tissue Engineering (Scaffold, Hydrogels), Application (Musculoskeletal, Oncology, Cardiovascular, Ophthalmology, Wound Care), Region - Global Forecast to 2027
	◆商品コード：BT4419-23 ◆発行会社（リサーチ会社）：MarketsandMarkets ◆発行日：2022年12月20日 ◆ページ数：192 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後24時間以内） ◆調査対象地域：グローバル ◆産業分野：バイオテクノロジー

◆販売価格オプション（消費税別）

Single User（1名様閲覧）	USD4,950 ⇒換算￥752,400	見積依頼/購入/質問フォーム
Multi User (Five User)	USD6,650 ⇒換算￥1,010,800	見積依頼/購入/質問フォーム
Corporate License (全社内共有可)	USD8,150 ⇒換算￥1,238,800	見積依頼/購入/質問フォーム

★MarketsandMarketsに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

マーケッツアンドマーケッツ社は、世界の再生医療市場規模が2022年122億ドルから2027年406億ドルに達し、予測期間中に年平均27.2％で成長すると予測しています。本調査報告書では、再生医療の世界市場を調査し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品別（細胞治療、遺伝子治療、組織工学）分析、用途別（筋骨格障害、腫瘍、皮膚科＆創傷治療、心血管疾患、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況、企業情報などの情報を整理しています。なお、当資料には、Novartis AG (Switzerland)、 Biogen (US)、Sarepta Therapeutics,Inc. (US)、Gilead Sciences,Inc. (US)、Amgen,Inc. (US)、Smith & Nephew plc (UK)、MEDIPOST Co.Ltd. (South Korea)、JCR Pharmaceuticals Co.Ltd (Japan)、Takeda Pharmaceutical Company (Japan)、CORESTEM Inc (South Korea)などの企業情報が含まれています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・世界の再生医療市場規模：製品別
- 細胞治療の市場規模
- 遺伝子治療の市場規模
- 組織工学の市場規模
・世界の再生医療市場規模：用途別
- 筋骨格障害における市場規模
- 腫瘍における市場規模
- 皮膚科＆創傷治療における市場規模
- 心血管疾患における市場規模
- その他用途における市場規模
・世界の再生医療市場規模：地域別
- 北米の再生医療市場規模
- ヨーロッパの再生医療市場規模
- アジア太平洋の再生医療市場規模
- 中南米の再生医療市場規模
- 中東・アフリカの再生医療市場規模
・競争状況
・企業情報

“再生医療市場は2022年の122億米ドルから2027年には406億米ドルに達すると予測され、予測期間中の年平均成長率は27.2%”
市場成長の原動力は、資金調達の可能性と研究開発への投資の増加、幹細胞やCAR-T細胞療法の臨床試験の増加、組織工学製品の進歩の高まりです。しかし、RM療法の高い治療費と商業化・規制が、予測期間中の市場成長を抑制すると予想されます。

“用途別では、筋骨格系疾患分野が再生医療市場で最大シェアを占める”
用途別に見ると、再生医療市場は筋骨格系疾患、創傷治療、腫瘍、眼疾患、歯科、その他の用途に区分されます。2021年には、筋骨格系疾患が最大の市場シェアを占めています。この背景には、整形外科疾患の有病率の上昇、老人人口の増加、幹細胞研究プロジェクトの増加、臨床研究/トライアルの増加、筋骨格系疾患を治療するための幹細胞製品の豊富なパイプラインなどがあります。

“アジア太平洋地域：再生医療市場で最も成長著しい地域”
アジア諸国における研究活動の活発化、研究資金の確保、バイオバンクや研究センターの増加がアジア太平洋地域の再生医療市場の成長を牽引していることなどから、アジア太平洋地域は予測期間中に最も高いCAGRで成長すると予測されています。

“北米：再生医療市場の最大シェア”
再生医療市場で最大シェアを占めるのは北米です。幹細胞バンクの設立、組織工学、幹細胞技術、生物製剤、組織工学、バイオマテリアルのような先端技術に基づく治療に対する需要の高まりなどが要因となります。

本レポートのために実施した一次インタビューは以下のように分類されます：
– 回答者別供給側80％、需要側20％
– 役職別 Cレベル25%、Dレベル20%、その他55％
– 地域別北米：50％、欧州：20％、アジア太平洋地域：20％、中南米：5％、中東・アフリカ：5％

主要プレイヤー
• Novartis AG (Switzerland)
• Biogen (US)
• Sarepta Therapeutics, Inc. (US)
• Gilead Sciences, Inc. (US)
• Amgen, Inc. (US)
• Smith & Nephew plc (UK)
• MEDIPOST Co., Ltd. (South Korea)
• JCR Pharmaceuticals Co., Ltd (Japan)
• Takeda Pharmaceutical Company (Japan)
• CORESTEM Inc (South Korea)
• Vericel Corporation (US)
• MIMEDX (US)
• Organogenesis Inc. (US)
• Medtronic plc (US)
• Orthocell Ltd. (Australia)
• Mesoblast Ltd (Australia)
• BioRestorative Therapies (US)
• Pluri Inc, (Israel)
• Tegoscience (South Korea)
• Anterogen Co., Ltd. (South Korea)
• Bluebird Bio (US)
• APAC Biotech (India)
• Shenzhen Sibiono Genetech Co., Ltd. (China)
• Aspect Biosystems (Canada)
• Athersys, Inc. (US)

調査範囲
本レポートは、再生医療市場の詳細な情報を提供します。製品、用途、地域などの異なるセグメントにわたる市場規模と今後の成長可能性を推定することを目的としています。また、主要市場プレイヤーの会社概要、最近の動向、主要市場戦略とともに、詳細な競合分析も掲載しています。

レポート購入の主な利点
本レポートは、再生医療市場全体とそのセグメントの収益数の最も近い概算値を提供することで、市場リーダー/新規参入者を支援します。また、利害関係者が競合状況をより良く理解し、より多くの洞察を得ることで、自社のビジネスをより良く位置付け、適切な市場参入戦略を立てるのに役立ちます。本レポートは、関係者が市場の鼓動を理解し、主要な市場促進要因、阻害要因、動向、機会、および課題に関する情報を提供することを可能にします。

❖ レポートの目次 ❖

1 INTRODUCTION 29
1.1 STUDY OBJECTIVES 29
1.2 MARKET DEFINITION 29
1.2.1 INCLUSIONS AND EXCLUSIONS 30
1.3 MARKET SCOPE 30
FIGURE 1 REGENERATIVE MEDICINE MARKET SEGMENTATION 30
1.3.1 YEARS CONSIDERED 31
1.4 CURRENCY CONSIDERED 31
1.5 LIMITATIONS 31
1.6 STAKEHOLDERS 32
1.7 SUMMARY OF CHANGES 32
2 RESEARCH METHODOLOGY 33
2.1 RESEARCH DATA 33
FIGURE 2 RESEARCH DESIGN 33
2.1.1 SECONDARY DATA 33
2.1.2 PRIMARY DATA 34
FIGURE 3 REGENERATIVE MEDICINE MARKET: BREAKDOWN OF PRIMARIES 35
2.2 MARKET SIZE ESTIMATION 36
2.2.1 BOTTOM-UP APPROACH 36
FIGURE 4 REGENERATIVE MEDICINE MARKET: BOTTOM-UP APPROACH 37
2.2.2 TOP-DOWN APPROACH 37
FIGURE 5 REGENERATIVE MEDICINE MARKET: TOP-DOWN APPROACH 37
2.3 GROWTH RATE ASSUMPTIONS 38
FIGURE 6 REGENERATIVE MEDICINE MARKET: CAGR PROJECTIONS, 2022–2027 38
FIGURE 7 REGENERATIVE MEDICINE MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 39
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 40
FIGURE 8 DATA TRIANGULATION METHODOLOGY 40
2.5 PRIMARY INSIGHTS 41
FIGURE 9 MARKET VALIDATION FROM PRIMARY EXPERTS 41
2.6 RESEARCH ASSUMPTIONS 41
2.7 RISK ANALYSIS 42
3 EXECUTIVE SUMMARY 43
FIGURE 10 REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION) 43
FIGURE 11 REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 44
FIGURE 12 GEOGRAPHICAL SNAPSHOT OF REGENERATIVE MEDICINE MARKET 45
4 PREMIUM INSIGHTS 46
4.1 REGENERATIVE MEDICINE MARKET OVERVIEW 46
FIGURE 13 AVAILABILITY OF FUNDING FOR RESEARCH AND INCREASING CLINICAL TRIALS IN REGENERATIVE MEDICINE TO DRIVE MARKET 46
4.2 NORTH AMERICA: REGENERATIVE MEDICINE MARKET 47
FIGURE 14 CELL THERAPY ACCOUNTED FOR LARGEST MARKET SHARE IN 2021 47
4.3 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, 2022 VS. 2027 (USD MILLION) 47
FIGURE 15 ALLOGENEIC THERAPY TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 47
5 MARKET OVERVIEW 48
5.1 INTRODUCTION 48
5.2 MARKET DYNAMICS 48
FIGURE 16 REGENERATIVE MEDICINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 48
5.2.1 DRIVERS 49
5.2.1.1 Availability of funding and rising investments in R&D 49
FIGURE 17 INVESTMENTS IN REGENERATIVE MEDICINE, 2017–2022 (USD BILLION) 49
TABLE 1 FUNDING INITIATIVES FROM CORPORATE PARTNERSHIPS IN 2022 (USD MILLION) 49
TABLE 2 FUNDING FROM CORPORATE PARTNERSHIPS IN 2021 (USD MILLION) 50
FIGURE 18 FUNDRAISING THROUGH PUBLIC OFFERINGS (IPO AND FOLLOW-ONS), 2021 (USD MILLION) 50
5.2.1.2 Increasing clinical trials for stem cell and CAR-T cell therapies 51
FIGURE 19 NUMBER OF STEM CELL THERAPY CLINICAL TRIALS (2015−2020) 51
5.2.1.3 Rising advancements in tissue-engineered products 51
5.2.2 RESTRAINTS 52
5.2.2.1 Issues associated with commercialization and regulatory compliance 52
5.2.2.2 High treatment cost of RM therapies 53
5.2.3 OPPORTUNITIES 53
5.2.3.1 Emerging economies 53
5.2.3.2 Rising cases of organ transplantation 54
5.2.4 CHALLENGES 55
5.2.4.1 Shortage of skilled professionals 55
5.3 PORTER’S FIVE FORCES ANALYSIS 55
TABLE 3 REGENERATIVE MEDICINE MARKET: PORTER’S FIVE FORCES ANALYSIS 55
5.3.1 THREAT OF NEW ENTRANTS 55
5.3.2 THREAT OF SUBSTITUTES 56
5.3.3 BARGAINING POWER OF BUYERS 56
5.3.4 BARGAINING POWER OF SUPPLIERS 56
5.3.5 INTENSITY OF COMPETITIVE RIVALRY 56

5.4 TECHNOLOGY ANALYSIS 57
FIGURE 20 KEY STEPS IN GENE THERAPY 57
TABLE 4 STEM CELL THERAPIES AND GENE THERAPIES 58
5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 58
FIGURE 21 REVENUE SHIFT TOWARD REGENERATIVE MEDICINE COMPANIES 59
5.6 SUPPLY CHAIN ANALYSIS 59
FIGURE 22 SUPPLY CHAIN ANALYSIS: REGENERATIVE MEDICINE MARKET 60
5.7 VALUE CHAIN ANALYSIS 60
FIGURE 23 VALUE CHAIN ANALYSIS: REGENERATIVE MEDICINE MARKET 61
5.8 ECOSYSTEM ANALYSIS 61
FIGURE 24 REGENERATIVE MEDICINE MARKET: ECOSYSTEM ANALYSIS 61
5.9 KEY CONFERENCES AND EVENTS IN 2022 62
5.9.1 REGENERATIVE MEDICINE CONFERENCES IN 2022 62
TABLE 5 REGENERATIVE MEDICINE CONFERENCES IN 2022 62
5.10 REGULATORY ANALYSIS 63
5.10.1 FDA APPROVALS 63
5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 63
TABLE 6 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 63
TABLE 7 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 64
TABLE 8 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 64
TABLE 9 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 65
5.11 PRICING ANALYSIS 65
TABLE 10 PRICES OF REGENERATIVE MEDICINES 65
5.11.1 REGENERATIVE MEDICINE MARKET: AVERAGE SELLING PRICE OF TREATMENT 66
5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 66
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 66
FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF REGENERATIVE MEDICINE PRODUCTS 66
5.12.2 BUYING CRITERIA FOR REGENERATIVE MEDICINE PRODUCTS 67
FIGURE 26 KEY BUYING CRITERIA FOR END USERS 67
6 REGENERATIVE MEDICINE MARKET, BY PRODUCT 68
6.1 INTRODUCTION 69
TABLE 11 REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 69
6.2 GENE THERAPY 69
6.2.1 STRONG PRODUCT PIPELINE DUE TO BROADENING APPLICATIONS IN DISEASE TREATMENT TO DRIVE MARKET 69
TABLE 12 REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY REGION, 2020–2027 (USD MILLION) 70
TABLE 13 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2020–2027 (USD MILLION) 70
TABLE 14 EUROPE: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2020–2027 (USD MILLION) 70
TABLE 15 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2020–2027 (USD MILLION) 71
6.3 CELL THERAPY 71
TABLE 16 REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 71
TABLE 17 REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY REGION, 2020–2027 (USD MILLION) 72
TABLE 18 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2020–2027 (USD MILLION) 72
TABLE 19 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2020–2027 (USD MILLION) 72
TABLE 20 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2020–2027 (USD MILLION) 73
6.3.1 STEM CELL THERAPY 73
TABLE 21 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 74
TABLE 22 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY REGION, 2020–2027 (USD MILLION) 74
TABLE 23 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2020–2027 (USD MILLION) 74
TABLE 24 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2020–2027 (USD MILLION) 75
TABLE 25 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2020–2027 (USD MILLION) 75
6.3.1.1 Cell Transplantations 75
6.3.1.1.1 Potential of Allo-SCT in treating AML to drive segment growth 75
TABLE 26 REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY REGION, 2020–2027 (USD MILLION) 76
TABLE 27 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 76
TABLE 28 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 76
TABLE 29 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 77
6.3.1.2 Stem Cell Therapy Products 77
TABLE 30 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 78
TABLE 31 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION) 78
TABLE 32 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION) 78
TABLE 33 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION) 79
6.3.1.2.1 Autologous Therapy 79
6.3.1.2.1.1 Low risk of post-treatment complications to support segment growth 79
TABLE 34 REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY REGION, 2020–2027 (USD MILLION) 80
TABLE 35 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2020–2027 (USD MILLION) 80
TABLE 36 EUROPE: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2020–2027 (USD MILLION) 80
TABLE 37 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2020–2027 (USD MILLION) 81
6.3.1.2.2 Allogeneic Therapy 81
6.3.1.2.2.1 Favorable scaling up of production processes to support segment growth 81
TABLE 38 REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY REGION, 2020–2027 (USD MILLION) 81
TABLE 39 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2020–2027 (USD MILLION) 82
TABLE 40 EUROPE: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2020–2027 (USD MILLION) 82
TABLE 41 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2020–2027 (USD MILLION) 82
6.3.2 CELL-BASED IMMUNOTHERAPY PRODUCTS 83
6.3.2.1 Adoption of T-cell therapy in cancer treatment to support market growth 83
TABLE 42 REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 83
TABLE 43 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION) 84
TABLE 44 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION) 84
TABLE 45 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY PRODUCTS, BY COUNTRY, 2020–2027 (USD MILLION) 84
6.4 TISSUE ENGINEERING (TE) 85
6.4.1 HIGH DEMAND FOR TE PRODUCTS IN DERMATOLOGY AND WOUND CARE APPLICATIONS TO DRIVE MARKET 85
TABLE 46 REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY REGION, 2020–2027 (USD MILLION) 85
TABLE 47 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2020–2027 (USD MILLION) 85
TABLE 48 EUROPE: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2020–2027 (USD MILLION) 86
TABLE 49 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2020–2027 (USD MILLION) 86

7 REGENERATIVE MEDICINE MARKET, BY APPLICATION 87
7.1 INTRODUCTION 88
TABLE 50 NUMBER OF CLINICAL TRIALS FOR REGENERATIVE MEDICINE PRODUCTS, BY APPLICATION, 2020 VS. 2021 88
TABLE 51 REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 88
7.2 MUSCULOSKELETAL DISORDERS 89
7.2.1 RISING RESEARCH ON MUSCULOSKELETAL REGENERATION AND PREVALENCE OF ORTHOPEDIC DISORDERS TO DRIVE MARKET 89
TABLE 52 REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2020–2027 (USD MILLION) 90
TABLE 53 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 90
TABLE 54 EUROPE: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 90
TABLE 55 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2020–2027 (USD MILLION) 91
7.3 ONCOLOGY 91
7.3.1 INCREASING STEM CELL TRANSPLANTS TO DRIVE MARKET 91
TABLE 56 INDICATIVE LIST OF COMMERCIALIZED REGENERATIVE CELL THERAPIES FOR ONCOLOGY APPLICATIONS 92
TABLE 57 REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY REGION, 2020–2027 (USD MILLION) 93
TABLE 58 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 94
TABLE 59 EUROPE: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 94
TABLE 60 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 94
7.4 DERMATOLOGY & WOUND CARE 95
7.4.1 RISING USE OF WOUND CARE BIOLOGICS IN ESTHETICS TO DRIVE MARKET 95
TABLE 61 INDICATIVE LIST OF REGENERATIVE MEDICINE PRODUCTS COMMERCIALIZED FOR TREATMENT OF ACUTE & CHRONIC WOUNDS 95
TABLE 62 REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY REGION, 2020–2027 (USD MILLION) 96
TABLE 63 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2020–2027 (USD MILLION) 96
TABLE 64 EUROPE: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2020–2027 (USD MILLION) 96
TABLE 65 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2020–2027 (USD MILLION) 97
7.5 CARDIOVASCULAR DISEASES 97
7.5.1 INCREASING USE OF MSCS FOR CLINICAL RESEARCH ON IHD TO SUPPORT MARKET GROWTH 97
TABLE 66 REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2020–2027 (USD MILLION) 98
TABLE 67 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 98
TABLE 68 EUROPE: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 99
TABLE 69 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION) 99
7.6 OPHTHALMOLOGY 99
7.6.1 REGENERATION OF EYE TISSUES FOR AMD TO SUPPORT MARKET GROWTH 99
TABLE 70 LIST OF PRODUCTS UNDER PIPELINE FOR REGENERATIVE MEDICINE IN OPHTHALMOLOGY 100
TABLE 71 REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY REGION, 2020–2027 (USD MILLION) 101
TABLE 72 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 101
TABLE 73 EUROPE: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 101
TABLE 74 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2020–2027 (USD MILLION) 102
7.7 OTHER APPLICATIONS 102
TABLE 75 REGENERATIVE MEDICINE MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 103
TABLE 76 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 103
TABLE 77 EUROPE: REGENERATIVE MEDICINE MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 103
TABLE 78 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 104
8 REGENERATIVE MEDICINE MARKET, BY REGION 105
8.1 INTRODUCTION 106
FIGURE 27 NUMBER OF PLAYERS IN REGENERATIVE MEDICINE MARKET, BY REGION, 2020−2022 106
TABLE 79 NUMBER OF CLINICAL TRIALS FOR REGENERATIVE MEDICINE (2022) 106
TABLE 80 REGENERATIVE MEDICINE MARKET, BY REGION, 2020–2027 (USD MILLION) 107
8.2 NORTH AMERICA 107
FIGURE 28 NORTH AMERICA: REGENERATIVE MEDICINE MARKET SNAPSHOT 108
TABLE 81 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 108
TABLE 82 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 109
TABLE 83 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 109
TABLE 84 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 109
TABLE 85 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 110
TABLE 86 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 110
8.2.1 US 110
8.2.1.1 Rising number of pipeline products for regenerative medicine to drive market 110
TABLE 87 PRODUCTS AWAITING APPROVALS IN THE US (2023) 111
TABLE 88 US: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 111
TABLE 89 US: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 111
TABLE 90 US: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 112
TABLE 91 US: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 112
TABLE 92 US: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 112
8.2.2 CANADA 113
8.2.2.1 Rising government initiatives for regenerative medicine research to drive market 113
TABLE 93 CANADA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 113
TABLE 94 CANADA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 113
TABLE 95 CANADA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 114
TABLE 96 CANADA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 114
TABLE 97 CANADA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 114
8.3 EUROPE 115
TABLE 98 PRODUCTS AWAITING APPROVALS IN EUROPE (2022) 115
TABLE 99 PRODUCTS AWAITING APPROVALS IN EUROPE (2023) 115
TABLE 100 EUROPE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 116
TABLE 101 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 116
TABLE 102 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 116
TABLE 103 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 117
TABLE 104 EUROPE: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 117
8.3.1 UK 117
8.3.1.1 Incorporating regenerative medicine into commercial healthcare services under NHS to drive market 117
TABLE 105 UK: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 118
TABLE 106 UK: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 118
TABLE 107 UK: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 118
TABLE 108 UK: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 119
TABLE 109 UK: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 119
8.3.2 GERMANY 119
8.3.2.1 Rising focus on clinical research and patent approvals to drive market 119
TABLE 110 GERMANY: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 120
TABLE 111 GERMANY: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 120
TABLE 112 GERMANY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 120
TABLE 113 GERMANY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 121
TABLE 114 GERMANY: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 121
8.3.3 FRANCE 121
8.3.3.1 Structured regulatory framework to drive RM product pipeline 121
TABLE 115 FRANCE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 122
TABLE 116 FRANCE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 122
TABLE 117 FRANCE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 122
TABLE 118 FRANCE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 123
TABLE 119 FRANCE: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 123
8.3.4 REST OF EUROPE 123
TABLE 120 REST OF EUROPE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 124
TABLE 121 REST OF EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 124
TABLE 122 REST OF EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 124
TABLE 123 REST OF EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 125
TABLE 124 REST OF EUROPE: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 125
8.4 ASIA PACIFIC 125
FIGURE 29 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET SNAPSHOT 126
TABLE 125 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 127
TABLE 126 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 127
TABLE 127 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 127
TABLE 128 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 128
TABLE 129 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 128
TABLE 130 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 128
8.4.1 JAPAN 129
8.4.1.1 Regulatory amendments to pharmaceutical legislation to drive commercialization of therapies 129
TABLE 131 JAPAN: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 129
TABLE 132 JAPAN: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 130
TABLE 133 JAPAN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 130
TABLE 134 JAPAN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 130
TABLE 135 JAPAN: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 131
8.4.2 CHINA 131
8.4.2.1 Favorable government support for development of regenerative medicine to drive market 131
TABLE 136 CHINA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 131
TABLE 137 CHINA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 132
TABLE 138 CHINA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 132
TABLE 139 CHINA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 132
TABLE 140 CHINA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 133
8.4.3 INDIA 133
8.4.3.1 Introduction of novel therapies for CVD and cancer to support market growth 133
TABLE 141 INDIA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 133
TABLE 142 INDIA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 134
TABLE 143 INDIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 134
TABLE 144 INDIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 134
TABLE 145 INDIA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 135

8.4.4 SOUTH KOREA 135
8.4.4.1 Strong research base and availability of funds to support market growth 135
TABLE 146 SOUTH KOREA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 136
TABLE 147 SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 136
TABLE 148 SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 136
TABLE 149 SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 137
TABLE 150 SOUTH KOREA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 137
8.4.5 REST OF ASIA PACIFIC 137
TABLE 151 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 138
TABLE 152 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 138
TABLE 153 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 138
TABLE 154 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 139
TABLE 155 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 139
8.5 LATIN AMERICA 139
8.5.1 RISING INCIDENCE OF DIABETES AND NEUROLOGICAL DISEASES TO DRIVE ADOPTION OF RM THERAPIES 139
TABLE 156 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 140
TABLE 157 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY CELL THERAPY, 2020–2027 (USD MILLION) 140
TABLE 158 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 140
TABLE 159 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 141
TABLE 160 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 141
8.6 MIDDLE EAST & AFRICA 141
8.6.1 INCREASE INCIDENCE OF CHRONIC CONDITIONS TO SUPPORT MARKET GROWTH 141
TABLE 161 MIDDLE EAST & AFRICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 142
TABLE 162 MIDDLE EAST & AFRICA: REGENERATIVE MEDICINE MARKET, BY CELL THERAPY, 2020–2027 (USD MILLION) 142
TABLE 163 MIDDLE EAST & AFRICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2020–2027 (USD MILLION) 142
TABLE 164 MIDDLE EAST & AFRICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 143
TABLE 165 MIDDLE EAST & AFRICA: REGENERATIVE MEDICINE MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 143
9 COMPETITIVE LANDSCAPE 144
9.1 OVERVIEW 144
9.2 STRATEGIES ADOPTED BY KEY PLAYERS 145
FIGURE 30 KEY DEVELOPMENTS IN REGENERATIVE MEDICINE MARKET
(JANUARY 2020 –NOVEMBER 2022) 145
9.3 MARKET SHARE ANALYSIS 145
FIGURE 31 REGENERATIVE MEDICINE MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2021) 146
FIGURE 32 REGENERATIVE MEDICINE MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS, BY PRODUCT (2021) 146
9.4 REVENUE SHARE ANALYSIS 147
FIGURE 33 REVENUE ANALYSIS FOR KEY COMPANIES 148
9.5 COMPANY EVALUATION QUADRANT 148
FIGURE 34 REGENERATIVE MEDICINE MARKET: COMPANY EVALUATION MATRIX (2021) 149
9.5.1 STARS 149
9.5.2 EMERGING LEADERS 150
9.5.3 PERVASIVE PLAYERS 150
9.5.4 PARTICIPANTS 150
9.6 COMPANY EVALUATION QUADRANT: STARTUPS/SMES 151
FIGURE 35 REGENERATIVE MEDICINE MARKET: COMPANY EVALUATION QUADRANT (2021) 151
9.6.1 PROGRESSIVE COMPANIES 151
9.6.2 STARTING BLOCKS 151
9.6.3 RESPONSIVE COMPANIES 152
9.6.4 DYNAMIC COMPANIES 152
9.7 COMPETITIVE BENCHMARKING 152
9.7.1 REGENERATIVE MEDICINE MARKET: LIST OF STARTUPS/SMES 152
TABLE 166 REGENERATIVE MEDICINE MARKET: LIST OF STARTUPS/SMES 152
9.7.2 REGENERATIVE MEDICINE MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS (STARTUPS/SMES) 153
TABLE 167 REGENERATIVE MEDICINE MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS (STARTUPS/SMES) 153
9.8 COMPETITIVE SCENARIO AND TRENDS 154
TABLE 168 REGENERATIVE MEDICINE MARKET: DEALS (2020−2022) 154
9.8.1 PRODUCT LAUNCHES AND REGULATORY APPROVALS (2020−2022) 155
TABLE 169 REGENERATIVE MEDICINE MARKET: PRODUCT LAUNCHES AND REGULATORY APPROVALS 155

10 COMPANY PROFILES 156
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
10.1 KEY PLAYERS 156
10.1.1 NOVARTIS AG 156
TABLE 170 NOVARTIS AG: BUSINESS OVERVIEW 156
FIGURE 36 NOVARTIS AG: COMPANY SNAPSHOT (2021) 157
10.1.2 BIOGEN, INC. 159
TABLE 171 BIOGEN: BUSINESS OVERVIEW 159
FIGURE 37 BIOGEN: COMPANY SNAPSHOT (2021) 159
10.1.3 SAREPTA THERAPEUTICS, INC. 161
TABLE 172 SAREPTA THERAPEUTICS: BUSINESS OVERVIEW 161
FIGURE 38 SAREPTA THERAPEUTICS: COMPANY SNAPSHOT (2021) 161
10.1.4 GILEAD SCIENCES, INC. 164
TABLE 173 GILEAD SCIENCES INC.: BUSINESS OVERVIEW 164
FIGURE 39 GILEAD SCIENCES, INC: COMPANY SNAPSHOT (2021) 165
10.1.5 AMGEN, INC. 167
TABLE 174 AMGEN INC: BUSINESS OVERVIEW 167
FIGURE 40 AMGEN, INC: COMPANY SNAPSHOT (2021) 168
10.1.6 SMITH & NEPHEW PLC 170
TABLE 175 SMITH & NEPHEW PLC: BUSINESS OVERVIEW 170
FIGURE 41 SMITH & NEPHEW PLC: COMPANY SNAPSHOT (2021) 171
10.1.7 MEDIPOST CO., LTD. 172
TABLE 176 MEDIPOST: BUSINESS OVERVIEW 172
FIGURE 42 MEDIPOST: COMPANY SNAPSHOT (2021) 172
10.1.8 JCR PHARMACEUTICALS CO., LTD. 174
TABLE 177 JCR PHARMACEUTICALS CO., LTD.: BUSINESS OVERVIEW 174
FIGURE 43 JCR PHARMACEUTICALS CO., LTD: COMPANY SNAPSHOT (2021) 175
10.1.9 TAKEDA PHARMACEUTICAL COMPANY LIMITED 176
TABLE 178 TAKEDA PHARMACEUTICAL COMPANY: BUSINESS OVERVIEW 176
FIGURE 44 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2021) 177
10.1.10 CORESTEM, INC. 178
TABLE 179 CORESTEM, INC.: BUSINESS OVERVIEW 178
TABLE 180 CORESTEM, INC.: REGULATORY APPROVALS 178
10.1.11 VERICEL CORPORATION 179
TABLE 181 VERICEL CORPORATION: BUSINESS OVERVIEW 179
FIGURE 45 VERICEL CORPORATION: COMPANY SNAPSHOT (2021) 179
10.1.12 MIMEDX 181
TABLE 182 MIMEDX: BUSINESS OVERVIEW 181
FIGURE 46 MIMEDX: COMPANY SNAPSHOT (2021) 181
10.1.13 ORGANOGENESIS, INC. 183
TABLE 183 ORGANOGENESIS INC: BUSINESS OVERVIEW 183
FIGURE 47 ORGANOGENESIS: COMPANY SNAPSHOT (2021) 183
10.1.14 MEDTRONIC PLC 185
TABLE 184 MEDTRONIC PLC: BUSINESS OVERVIEW 185
FIGURE 48 MEDTRONIC PLC: COMPANY SNAPSHOT (2021) 186
10.1.15 ORTHOCELL LTD. 187
TABLE 185 ORTHOCELL: BUSINESS OVERVIEW 187
FIGURE 49 ORTHOCELL LIMITED: COMPANY SNAPSHOT (2021) 187
10.2 OTHER PLAYERS 188
10.2.1 MESOBLAST LTD. 188
10.2.2 BIORESTORATIVE THERAPIES, INC. 188
10.2.3 PLURI INC. 189
10.2.4 TEGOSCIENCE 189
TABLE 186 TEGOSCIENCE: BUSINESS OVERVIEW 189
10.2.5 ANTEROGEN CO., LTD. 190
TABLE 187 ANTEROGEN CO., LTD.: BUSINESS OVERVIEW 190
10.2.6 BLUEBIRD BIO 190
TABLE 188 BLUEBIRD BIO: BUSINESS OVERVIEW 190
10.2.7 STEMPEUTICS RESEARCH 191
TABLE 189 STEMPEUTICS RESEARCH: BUSINESS OVERVIEW 191
10.2.8 SHENZHEN SIBIONO GENETECH CO., LTD. 191
TABLE 190 SHENZHEN SIBIONO GENETECH CO., LTD.: BUSINESS OVERVIEW 191
10.2.9 ASPECT BIOSYSTEMS 192
TABLE 191 ASPECT BIOSYSTEMS: BUSINESS OVERVIEW 192
10.2.10 ATHERSYS, INC. 192
TABLE 192 ATHERSYS, INC.: BUSINESS OVERVIEW 192
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
11 APPENDIX 193
11.1 DISCUSSION GUIDE 193
11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 196
11.3 CUSTOMIZATION OPTIONS 198
11.4 RELATED REPORTS 198
11.5 AUTHOR DETAILS 199

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の再生医療市場：製品別（細胞治療（自己、同種）、遺伝子治療、組織工学（足場、ハイドロゲル））、用途別、地域別(Regenerative Medicine Market by Product (Cell Therapy (Autologous, Allogenic), Gene Therapy, Tissue Engineering (Scaffold, Hydrogels), Application (Musculoskeletal, Oncology, Cardiovascular, Ophthalmology, Wound Care), Region - Global Forecast to 2027)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

世界の再生医療市場：製品別（細胞治療（自己、同種）、遺伝子治療、組織工学（足場、ハイドロゲル））、用途別、地域別

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp